SCHEMBL20577962

SCHEMBL20577962

Cc1cn(-c2cc(C(=O)Nc3ccc(F)c(OC(=O)NC(C)(C)C)c3F)cc(C(F)(F)F)c2)cn1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 1/20 0.51
KDR P35968 1/20 0.51
NR2E1 Q9Y466 7/20 0.51
KDM4E B2RXH2 1/20 0.48
POLB P06746 1/20 0.48
RECQL P46063 1/20 0.48
BRAF P15056 4/20 0.46
RAF1 P04049 3/20 0.46
EPHB2 P29323 1/20 0.46
LDLR P01130 1/20 0.45
KIT P10721 1/20 0.45
PCSK9 Q8NBP7 1/20 0.45
MAPT P10636 1/20 0.45
ABL1 P00519 4/20 0.45
BCR P11274 4/20 0.45
EGFR P00533 1/20 0.43
LCK P06239 1/20 0.43
FYN P06241 1/20 0.43
YES1 P07947 1/20 0.43
LYN P07948 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20577790 0.83 KDR (0.59) CSF1RKDRNR2E1KDM4EPOLB
SCHEMBL20577789 0.79 NR2E1 (0.54) CSF1RKDRNR2E1KDM4EPOLB
SCHEMBL15381980 0.79 NR2E1 (0.61) CSF1RNR2E1KDM4EPOLBRECQL
SCHEMBL20577779 0.78 PTGS1 (0.51) KDM4EPOLBMAPT
SCHEMBL20578050 0.75 NR2E1 (0.49) CSF1RKDRNR2E1KDM4EPOLB
SCHEMBL12171374 0.73 NR2E1 (0.63) CSF1RNR2E1KDM4EPOLBRECQL
SCHEMBL18239969 0.73 NR2E1 (0.63) CSF1RNR2E1KDM4EPOLBRECQL
SCHEMBL4552209 0.73 NR2E1 (0.61) CSF1RNR2E1KDM4EPOLBRECQL
SCHEMBL12154454 0.72 NR2E1 (0.60) CSF1RNR2E1KDM4EPOLBRECQL
SCHEMBL28662285 0.72 NR2E1 (0.55) CSF1RNR2E1KDM4EPOLBRECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10844062-B2 Pyridine derivative inhibiting RAF kinase and vascular endothelial growth factor receptor, method for preparing same, pharmaceutical composition containing same, and use thereof INCHEON UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION (KR) 2020-11-24 US disclosed
US-20190300531-A1 Pyridine Derivative Inhibiting RAF Kinase and Vascular Endothelial Growth Factor Receptor, Method for Preparing Same, Pharmaceutical Composition Containing Same, and Use Thereof SAMJIN PHARMACEUTICAL CO., LTD. (KR) 2019-10-03 US disclosed
EP-3412670-A1 PYRIDINE DERIVATIVE INHIBITING RAF KINASE AND VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR, METHOD FOR PREPARING SAME, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF Samjin Pharmaceutical Co., Ltd. (KR) 2018-12-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190300531-A1 Pyridine Derivative Inhibiting RAF Kinase and Vascular Endothelial Growth Factor Receptor, Method for Preparing Same, Pharmaceutical Composition Containing Same, and Use Thereof BRAF, KDR, RAF1 CSF1R 312/4885KDR 2/4885NR2E1 1130/4885
US-10844062-B2 Pyridine derivative inhibiting RAF kinase and vascular endothelial growth factor receptor, method for preparing same, pharmaceutical composition containing same, and use thereof BRAF, KDR, RAF1 CSF1R 312/4885KDR 2/4885NR2E1 1130/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.